{"id":"W2127154017","doi":"10.1016/j.ctrv.2009.08.001","title":"Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions","year":2009,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Pfizer","keywords":"Lapatinib; Medicine; Trastuzumab; Tyrosine kinase; Receptor tyrosine kinase; Breast cancer; Tyrosine-kinase inhibitor; ErbB; Monoclonal antibody; Cancer research; Cancer; Pharmacology; Internal medicine; Receptor; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002785093,0.001136006,0.004046392,0.0003923787,0.0002617133,0.0001058726,0.0001409158,0.0003427042,0.0006545746],"category_scores_gemma":[0.00001876416,0.0007380182,0.0006171918,0.0009881448,0.0002046258,0.0001325695,0.00009885655,0.0007524151,0.00006257434],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004031075,"about_ca_system_score_gemma":0.002038059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001882783,"about_ca_topic_score_gemma":0.0005836556,"domain_scores_codex":[0.9959797,0.0003494605,0.001057611,0.00127258,0.0004366808,0.0009039633],"domain_scores_gemma":[0.9975273,0.00007831456,0.0005105413,0.0008544147,0.0001488652,0.0008805487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002711262,0.0002662917,0.0005707325,0.02822364,0.0002861657,0.00003348587,0.0001040379,2.240253e-8,5.60484e-7,0.000008983382,0.01670652,0.9537724],"study_design_scores_gemma":[0.001068529,0.000315109,0.0005556715,0.05066307,0.004489139,0.0001620397,0.00001607143,5.846521e-7,0.00000212115,0.000003218061,0.9421912,0.0005332504],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002376219,0.99,3.980084e-7,0.001138764,0.00136339,0.005611215,0.001425887,0.00008709894,0.000349462],"genre_scores_gemma":[0.000001517904,0.9912357,0.00008468509,0.0001083198,0.003741029,0.002849995,0.0004047716,0.0001158262,0.001458131],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9532392,"threshold_uncertainty_score":0.9997923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08835437902740187,"score_gpt":0.4363174976594466,"score_spread":0.3479631186320448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}